Search Results

You are looking at 51 - 60 of 489 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

Highlights of the NCCN Oncology Research Program

by the ORP. This feature highlights an NCCN study funded through the grant mechanism. A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced-Stage or Recurrent Endometrioid Endometrial

Full access

Simplifying Guidelines: We Only Need One Adjuvant Chemotherapy Regimen for Breast Cancer

Harold J. Burstein

regimens dramatically. In fact, you only need 1: AC (doxorubicin/cyclophosphamide) followed by paclitaxel. Here is the following evidence. The Oxford overview, based on treatment of over 100,000 women in adjuvant trials, suggests that all women who need

Full access

CLO21-020: Pembrolizumab in Metastatic Non-Squamous and Squamous Non-Small Cell Lung Cancer (NSCLC): Real World Data Results

Augustine Lau, Jessy Delaisla, Jeff Dang, Sang Chau, and Andrew Hertler

control group. For those with advanced squamous NSCLC, the addition of pembrolizumab to paclitaxel/nab-paclitaxel with carboplatin provided a 6.4 months PFS advantage versus 4.8 months in the control group. Methods: The sample was obtained from a

Full access

Oncology Research Program

scientific peer-review process and are overseen by the ORP. An NCCN study funded through the grant mechanism is highlighted below. Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced

Full access

Oncology Research Program

scientific peer-review process and are overseen by the ORP. An NCCN study funded through the grant mechanism is highlighted below. A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in

Full access

Oncology Research Program

Armstrong, MD • 919-668-8108 ClinicalTrials.gov Identifier: NCT00887640 Weekly Nanoparticle Albumin-Bound Paclitaxel Plus Weekly Cetuximab Plus Radiation Therapy in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma Principal

Full access

Rational Use of Cytotoxic Chemotherapy for Recurrent Ovarian Cancer

Joyce Liu and Ursula Matulonis

. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer . N Engl J Med 1996 ; 334 : 1 – 6 . 3. Ozols RF Bundy BN Greer BE . Phase III trial of carboplatin and paclitaxel compared

Full access

Oncology Research Program

advanced melanoma Contact: Roswell Park Cancer Institute • 877-275-7724 • AskRPCI@roswellpark.org ClinicalTrials.gov Identifier: NCT01533948 Phase I Trial of Intraperitoneal Nab-Paclitaxel (Abraxane) in the Treatment of Advanced Malignancies

Full access

Oncology Research Program

scientific peer-review process and are overseen by the ORP. NCCN-sponsored studies funded through the grant mechanism are highlighted below. Phase I Study of Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage

Full access

Oncology Research Program

scientific peer-review process and are overseen by the ORP. NCCN studies funded through the grant mechanism are highlighted below. Phase I Study of Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA